Precision medicine needs randomized clinical trials
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://www.nature.com/articles/nrclinonc.2017.8.pdf
Reference88 articles.
1. Masters, G. A. et al. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J. Clin. Oncol. 33, 786–809 (2015).
2. US Food & Drug Administration Center for Drug Evaluation & Research. Novel New Drugs 2014 — Summary — January 2015. FDA http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM430299.pdf (2014).
3. Malik, S. M. et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin. Cancer Res. 20, 2029–2034 (2014).
4. Khozin, S. et al. FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin. Cancer Res. 21, 2436–2439 (2015).
5. Ratain, M. J. & Sargent, D. J. Optimising the design of phase II oncology trials: the importance of randomisation. Eur. J. Cancer 45, 275–280 (2009).
Cited by 59 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Bayesian Sequential Design for Identifying and Ranking Effective Patient Subgroups in Precision Medicine in the Case of Counting Outcome Data with Inflated Zeros;Journal of Personalized Medicine;2023-10-30
2. Early Efficacy End Points in Neoadjuvant Rectal Cancer Trials: Surrogacy Revisited;Journal of Clinical Oncology;2023-10-27
3. Estimation of treatment effects in early-phase randomized clinical trials involving external control data;Journal of Biopharmaceutical Statistics;2023-10-12
4. Trial Design for Cancer Immunotherapy: A Methodological Toolkit;Cancers;2023-09-21
5. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology;Science Translational Medicine;2023-07-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3